Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group CL.3 (CALGB 10404) -- A Genetic Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia -- has met its accrual goal.

This trial will close to new accrual at 5pm ET today (Friday August 17, 2012). Step 2 registrations will continue as required.

Canadian Cancer Trials Group accrued 58 patients to this trial, which represents 14% of the total accrual.

Thanks go to all participating centres, staff and patients who helped to make this trial a success!